Pesquisar
Biohaven Ltd
BHVNAdicionar à lista de desejos
13.670USD
-1.180-7.95%
Fechamento 09-23 16:00（ET）
2.06BValor de mercado
PerdaP/L TTM
Sobre o Biohaven Ltd Empresa
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Biohaven Ltd Perfil
Código da empresaBHVN
Nome da EmpresaBiohaven Ltd
Data de listagemSep 23, 2022
CEOCoric (Vlad)
Número de funcionários256
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 23
Endereço215 Church Street
CidadeNEW HAVEN
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal06510
Telefone12034040410
Sitehttps://www.biohaven.com/
Código da empresaBHVN
Data de listagemSep 23, 2022
CEOCoric (Vlad)
Executivos da empresa Biohaven Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
67.72K
+45.11%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
67.72K
+45.11%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
67.72K
+45.11%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Perguntas frequentes
Quem são os cinco principais acionistas de Biohaven Ltd?
Os cinco principais acionistas de Biohaven Ltd são: Dr. Gregory Hugh (Greg) Bailey, M.D.
Quantas instituições possuem ações da Biohaven Ltd (BHVN)?
Em 2026Q1, 610 instituições possuíam ações da Biohaven Ltd, com valor de mercado aproximado de 138.20M, representando 91.79% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 37866485.00.